UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes. The funding from the UK’s innovation agency will be ...

CAMBRIDGE, England & BRISBANE, Calif.--(BUSINESS WIRE)-- Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell ...

CAMBRIDGE, United Kingdom and TOKYO, July 5, 2022 /PRNewswire/ -- Mogrify Limited (CEO: Darrin M. Disley, Ph.D., "Mogrify ® "), a biopharmaceutical company transforming the lives of patients through a ...

Cell Mogrify (Mogrify), has been granted funding by the UK’s innovation agency, Innovate UK, to accelerate regenerative cell therapies. United Kingdom-based company, Cell Mogrify (Mogrify), has been ...

Mogrify Limited (Mogrify ®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the ...

Sangamo Therapeutics has struck a deal with Mogrify to gain access to a source of cells for use in its allogeneic CAR-Treg therapies. The agreement sees Sangamo pay an upfront fee to get Mogrify to ...

Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed funding, bringing the total raised to $3.7 million USD ...

Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has announced the ...

“Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy,” said Dr. Darrin M. Disley OBE, CEO, Mogrify. “The ...

Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has announced the ...